Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 13/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 3/20 | 0.38 |
| ▸ | GSK3A | P49840 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.35 |
| ▸ | RPS6KA1 | Q15418 | 2/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19794454 | 0.91 | TRPV1 (0.40) | RPS6KA3CYP2A6 | |
| SCHEMBL19794405 | 0.85 | NPC1 (0.40) | DGAT1KIF11 | |
| SCHEMBL18015681 | 0.84 | KIF11 (0.37) | RPS6KA3DGAT1KIF11GSK3AGSK3B | |
| SCHEMBL22914975 | 0.84 | KIF11 (0.37) | DGAT1KIF11 | |
| SCHEMBL21202899 | 0.82 | RPS6KA3 (0.35) | RPS6KA3GSK3AGSK3BRPS6KA2RPS6KA1 | |
| SCHEMBL27344642 | 0.81 | KIF11 (0.43) | KIF11CYP2A6 | |
| SCHEMBL31695223 | 0.81 | KIF11 (0.43) | KIF11CYP2A6 | |
| SCHEMBL21721907 | 0.81 | MEN1 (0.38) | — | |
| SCHEMBL19794448 | 0.80 | TRPV1 (0.46) | — | |
| SCHEMBL19933667 | 0.80 | FAAH (0.39) | DGAT1KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11024815-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2021-06-01 | — | — | US | disclosed |
| EP-3254317-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-07-31 | — | — | EP | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| US-20180026209-A1 | Metal Complexes | MERCK PATENT GMBH (DE) | 2018-01-25 | — | — | US | disclosed |
| WO-2016124304-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2016-08-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11024815-B2 | Metal complexes | EXOC4, EXOC3, TIMCC | RPS6KA3 4252/4885DGAT1 1835/4885KIF11 2722/4885 |
| US-20180026209-A1 | Metal Complexes | AP3M1, AP2M1, SOD1 | RPS6KA3 3414/4885DGAT1 1328/4885KIF11 1128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.